It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Surgical site infections and antimicrobial resistance remain major challenges globally
Subscribe To Our Newsletter & Stay Updated
